In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Hold rating on Alaunos Therapeutics (TCRT – Research Report). The company’s shares closed yesterday at $1.01.
According to TipRanks, Ramakanth is an analyst with an average return of -14.9% and a 29.46% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, Alaunos Therapeutics, and MiMedx Group.
Alaunos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.38.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.01 and a one-year low of $0.41. Currently, Alaunos Therapeutics has an average volume of 3.8M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More on TCRT:
